Xealth Inc., of Seattle, closed a series A financing with an additional $3 million from new investors Atrium Health, Cleveland clinic and Memorialcare Innovation Fund. The proceeds, which now total $14 million, will go toward further developing and deploying the company's digital prescribing and analytics platform. The company focuses on helping health systems organize and utilize digital health tools to optimize workflow, patient engagement and financial results.

Cochlear Ltd., of Sydney, received U.S. FDA approval for its Nucleus Profile Plus cochlear implant and the Nucleus 7 sound processor's new built-in connectivity, enabling direct streaming with compatible Android smartphones. The implant will be commercially available in the U.S. later this month.

The FDA has given its final nod to W.L. Gore & Associates Inc. to market the Cardioform ASD occluder, aimed at correcting a congenital anomaly that causes a hole in the wall between the two upper chambers of the heart. The device, approved May 28, marks the newest addition to the Flagstaff, Ariz.-based health care and consumer products company's Cardioform occluder product line. The Cardioform ASD occluder is indicated for the percutaneous closure of ostium secundum atrial septal defects (ASDs).